Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis. Issue 29 (23rd July 2021)

• Record Type: Journal Article
• Authors: Wang, Zunlian; Huang, Min; Yu, Bin; Huang, Yilan; Zheng, Silin; Yang, Xuping; Ning, Hong
• Other Names: Cruz. Jorddy Neves section editor.
• Is Part Of: Medicine. Volume 100:Issue 29(2021)
• Publication Date: 2021-07-23
• Subjects: adalimumab -- baricitinib -- disease-modifying anti-rheumatic drugs -- network meta-analysis -- rheumatoid arthritis -- sarilumab -- sirukumab -- tocilizumab; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000026524
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Objective: To compare efficacy and safety indicators of disease-modifying antirheumatic drugs, Sarilumab, Sirukumab, Baricitinib, Tocilizumab and Adalimumab in rheumatoid arthritis treatment by a network meta-analysis. Methods: Medline, Embase, Web of Science, The Food and Drug Administration web site, and Cochrane library were searched from build to June 1, 2020. Clinical randomized controlled trails of these 5 drugs for rheumatoid arthritis were collected for network meta-analysis. Results: A total of 4 randomized controlled trails with 2070 patients were obtained. The results of the network meta-analysis showed that: There was no significant difference between the 4 drugs (Sarilumab, Sirukumab, Adalimumab, and Tocilizumab) ( P > .05) in terms of American College of Rheumatology 20. There was no significant difference between the 5 drugs in the aspect of the America College of Rheumatology 50% and 70% (American College of Rheumatology 50, American College of Rheumatology 70) ( P > .05). There was no significant difference between the 3 drugs (Sarilumab, Sirukumab, Adalimumab) in terms of reducing disease activity score 28-erythrocyte sedimentation rate in patients ( P > .05). No significant difference was observed among the 5 drugs in terms of incidence of adverse reactions, serious adverse reactions and withdrawal adverse reactions ( P > .05). The results of the ranked probability plot indicated that Tocilizumab and Sarilumab outperform other drugs in terms of efficacy and safety. Conclusion: The results of the ranking of the 5 drugs showed that Tocilizumab and Sarilumab had the best efficacy and safety.